You are here

Home » Content

Tirodektomi sonrası verilen tiroksin tedavisinin kemik mineral dansitesine etkisi

The effect of thyroxine treatment on bone mineral density given after thyroidectomy

Journal Name:

  • Selçuk Tıp Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
The use of thyroxin for suppression or replacement therapy following thyroidectomy is very common. But its effect on bone mineral density (BMD), is beeing debated. The aim of this study is to determine whether long-term thyroxine therapy is a risk factor for the development of secondary osteoporosis in premenopousal and postmenopousal women after thyroidectomy. 33 premenopousal and 17 postmenopousal female patients who had thyroidectomy for different indications in Ankara Numune Teaching and Research Hospital department of fifth surgery clinic between September 2001 and October 2003 were included in this study. The patients were put on 50-200mcg/day L-thyroxine postoperatively and dosage was adjusted on routine follow-ups. BMD of patients at lumbar, femoral neck and Ward' triangle regions was measured using dual energy X-ray absorp¬tiometry preoperatively and postoperatively after 6th month and first year. There was no significant difference in thyroid hormone levels and l-thyroxine dose between the premenopousal and postmenopousal patients (p>0.05j. There was no significant difference in preoperative, postoperative 6th month and postoperative first year BMD of patients groups (p>0.05). No correlation was detected between the BMD and preoperative diag¬nosis, surgical procedure, the dose and duration of L-thyroxine therapy. In conclusion we think that long-term thyroxine therapy is not a single prédisposant factor for decrease in BMD.
Bookmark/Search this post with
Abstract (Original Language): 
Tiroidektomi sonrası tiroksinin süpresif veya idame amaçlı kullanımı oldukça yaygındır. Ancak uzun dönem tiroksin tedavisinin kemik mineral dansitesine (KMD) etkisi tartışmalıdır. Bu çalışmada amaç tiroidektomi sonrası uzun dönem tiroksin tedavisi alan premenopozal ve postmenopozal kadınların sekonder osteoporoz açısından bir risk altında olup olmadığının belirlenmesidir. Ankara Numune Eğitim ve Araştırma Hastanesi 5. Cerrahi Kliniğinde Eylül 2001 - Ekim 2003 tarihleri arasında farklı nedenlerle tiroidektomi uygulanan 33 premenopozal ve 17 postmenopozal kadın hasta çalışmaya alındı. Tiroidektomi sonrası 50-200 mcg/gün L-tiroksin baş/anan hastalara daha sonraki kontrol/erde gerektiğinde doz ayarlaması yapıldı. Hastalarda preoperatif, postoperatif 6. ay ve 1.yılda tomber vertebra, femur boynu ve Wards' üçgeninde Dual-Energy X-Ray absorbsiyometri yöntemiyle KMD ölçümleri yapıldı. Premenopozal ve postmenopozal hastalar arasında tiroid hormon düzeyleri ve L-tiroksin dozu açısından istatistiksel anlamlı fark saptanmadı (p>0.05j. Her iki grupta da preoperatif, postoperatif 6.ay ve l.yıl KMD'leri açısından anlamlı fark saptanmadı (p>0.05j. Premenopozal ve postmenopozal hastalarda preoperatif tanı, yapılan cerrahi işlem, L-tiroksin dozu ve süresinin KMD ile ilişkisi bulunamamıştır. Tiroidektomi sonrası uzun dönem tiroksin tedavisinin tek başına KMD'sinde azalmaya sebep olacak bir etken olmadığını düşünmekteyiz.
FULL TEXT (PDF): 
PDF icon arastirmax-tirodektomi-sonrasi-verilen-tiroksin-tedavisinin-kemik-mineral-dansitesine-etkisi.pdf
  • 4
104-108
  • Turkish

REFERENCES

References: 

1. Baran DT. Hyperthyroidism, thyroid hormone replace¬ment and osteoporosis, m: Favus MJ; ed. Primer on the metabolic bone disease and disorders of mineral metabo¬lism. 3rd ed. Philadelphia: Lıppıncott Raven; 1996:286-8
2. Sijanovi S, Kamer I Bone loss in premenopousal women on long term suppressive therapy with thyroid hormone. Medscape General Medicine 3(4). 200!
3. Lanjani B, Gharibdoost F, Pajouhi M, Sadjadi A Aghakhani S, Eshraghian R, et al. Effects of levothyroxine suppressive therapy on bone mineral density in pre¬menopousal women. Journal of Clinical Pharmacy & Therapeutics 2004; 29:1
4. Garton M, Reıd I, Loveridge N. Robins S, Murchison L. Beckett G, et al. Bone mineral densiiy and metabolism in premenopousal women taking L-throxine replacement. Clin Endocrinol 1994;41 jsuppl)."747-55
5. Fujiyama K, Kimyama T, Iso M. Suppresive doses of thy-roxine do not accelerate age-related bone loss in late postmenopousal women. Thyroid 1995 ;5: I A
6 Müller CG, Bayley TA Harrison JE, Tsang R. Possible limit¬ed bone loss with suppresive thyroxine therapy is unlike¬ly to have clinical revelance. Thyroid 1995;5:2A
7. Gorres G. Kaim A 0:r_e A. Gotze M, Muller-Brand J. Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma. Eur J NuclMed. 1996;23:690-2
8. Foldes J. Tarjan G, Szathmari M. Varga F, Krasznai I, Horvath C. Bone mineral density in patients with endoge-nous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis. Clin Endocrinol (Oxf). 1993;(5):52l-7
9. Diamond T, Nery L. Hales I. A therapeutic dilemma: sup-pressive doses of thyroxine significantly reduce bone min-eral measurements in both premenopausal and post-menopausal women with thyroid carcinoma. J Clin Endocrinol Metab. 1991 ;72:I 184-8
10. Faber J, Galloe AM. Changes in bone mass during pro¬longed subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol. 1994.130:350-6

11.Mora S, Weber G, Marenzi K. Signcrini E, Rovelli R, Proverbio MC. Chiumello G. Longitudinal changes of bone density and bone resorption in nyperthyroid giriş during treatment. J Bone Miner Res. 1 999; 14:1971-7
12. Broulik PD, Rosenkrancova J. Ruzicka P, Sedlacefc R. Effects of triiodothyronine and estrogen administration on bone mass, mineral content and bone strength in male rats. Horm Metah Res. 2003 ;35:527-3 1
13. Ishihara C, Kushida K, Takahashi M, Koyama S, Kawana K, Atsumi K. Inoue T. Effect of thyroid hormone on bone and mineral metabolism in rat: evaluation by biochemical markers. Endocr Res. 1997;23:167-80
14. FranklynJA Betteridge J. DaykinJ. Ho'der R, Oates GD, Parle JV, Lilley J.Heath DA, Sheppard MC. Long-term thy¬roxine treatment and bone mineral density. Lancet J 992 ;340:9-l3
15. Hawkins F, Rigopoulou D, Papapietro K. Lopez MB. Spinal bone mass after long-term treatment with L-thy¬roxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis. Calcif Tissue Int. 1994 ;54:l6-9
16. Kung AW, Lorentz T, Tarn SC. Thyroxine suppressive the¬rapy decreases bone mineral density in post-menopausal women. Clin Endocrinol (Oxf). 1993 ,39:535-40.
17. Quan ML, Pasieka JL. Rorstad O. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the lite-ratüre. J Surg Oncol. 2002 .79:02-9
18. Hanna FW. Pettit RJ. Amrnari F, Evans WD, Sandeman D, Lazarus JH.Effect of replacement doses of thyroxine on bone mineral density. Clin Endocrinol (Oxf). I998;48: 229-34
19. Baldini M. Gallazzi M. Orsattı A Fossati S. Leonardı P, Cantaiamessa L Treatment of benign nodular goitre with mildly suppressive doses of L-thyroxine effects on bone mineral density and on nodule size. J Intern Med. 2002 ; 251:407-14

Thank you for copying data from http://www.arastirmax.com